N,N'-diallyltartardiamide: cross linking reagent; RN given refers to (R-(R*,R*))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 98486 |
CHEBI ID | 184080 |
SCHEMBL ID | 107767 |
MeSH ID | M0054445 |
Synonym |
---|
butanediamide, 2,3-dihydroxy-n,n'-di-2-propenyl- |
CBDIVE_003321 |
n,n'-diallyl-2,3-dihydroxy-butanediamide |
n~1~,n~4~-diallyl-2,3-dihydroxysuccinamide |
nsc145415 |
nsc-145415 |
28843-34-7 |
n,n'-diallyltartardiamide |
D-0950 |
datd |
n,n'-diallyltartramide |
inchi=1/c10h16n2o4/c1-3-5-11-9(15)7(13)8(14)10(16)12-6-4-2/h3-4,7-8,13-14h,1-2,5-6h2,(h,11,15)(h,12,16) |
2,3-dihydroxy-n,n'-di(prop-2-enyl)butanediamide |
zrkleahgbndkhm-uhfffaoysa- |
D1539 |
(+)-n,n'-diallyl-l-tartramide |
(+)-n,n'-diallyl-l-tartardiamide |
2,3-dihydroxy-n,n'-bis(prop-2-enyl)butanediamide |
CHEBI:184080 |
n,n'-diallyl-2,3-dihydroxysuccinamide |
(2r,3r)-2,3-dihydroxy-n,n'-bis(prop-2-enyl)butanediamide |
AKOS004903293 |
ai3-62352 |
nsc 145415 |
einecs 249-267-7 |
FT-0629377 |
FT-0629378 |
FT-0629435 |
SCHEMBL107767 |
n,n'-diallyl-l-(+)-tartardiamide |
butanediamide, 2,3-dihydroxy-n,n'-di-2-propenyl-, [r-(r*,r*)]- |
(+)-n,n'-diallyltartardiamide |
ZRKLEAHGBNDKHM-UHFFFAOYSA-N |
n,n'-diallyl tartardiamide |
butanediamide,2,3-dihydroxy-n1,n4-di-2-propen-1-yl- |
n1,n4-diallyl-2,3-dihydroxysuccinamide |
2,3-dihydroxy-n~1~,n~4~-di(prop-2-en-1-yl)butanediamide |
DTXSID50866693 |
Class | Description |
---|---|
fatty amide | A monocarboxylic acid amide derived from a fatty acid. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 6 (54.55) | 18.7374 |
1990's | 3 (27.27) | 18.2507 |
2000's | 2 (18.18) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (9.09%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (90.91%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |